Association of visfatin gene polymorphism rs4730153 with anthropometric characteristics, visfatin level, insulin resistance and lipid metabolism in Iranian diabetic/pre-diabetic population

authors:

avatar Reyhaneh karimi 1 , avatar Masoumeh Nezhadali 1 , * , avatar Mehdi Hedayati ORCID 2

Dept. of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran
- Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Science, Shahid Beheshti University of Medical Science, Tehran, Iran

how to cite: karimi R, Nezhadali M, Hedayati M. Association of visfatin gene polymorphism rs4730153 with anthropometric characteristics, visfatin level, insulin resistance and lipid metabolism in Iranian diabetic/pre-diabetic population. koomesh. 2021;23(5):e154076. https://doi.org/10.5812/koomesh-154076.

Abstract

Introduction: Visfatin is a pro-inflammatory adipokine that is abundantly expressed in visceral adipose tissue. The cytokine visfatin is increased in obesity and type 2 diabetes. Visfatin is an insulin-mimetic adipokine that may also play a role in the development of diabetes and inflammatory reactions. The aims of the present study were to investigate the association of visfatin gene polymorphism rs4730153 with anthropometric characteristics, visfatin level, insulin resistance and lipid metabolism in an Iranian diabetic/pre-diabetic population. Materials and Methods: This case-control study was conducted on 70 participants with pre-diabetes/diabetes and 70 participants as a control group. Serum levels of insulin and visfatin were measured using ELISA kits and other parameters were determined by standard methods. The genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The results showed no significant differences in the levels of cholesterol, insulin, visfatin between diabetic and non-diabetic subjects (P>0.05). Regression analysis of genotypes showed that rs4730153 polymorphism is not associated with type 2 diabetes (P>0.05). There was no significant difference in genotype distribution and allelic frequencies between the insulin- sensitive, insulin- resistance, and intermediate groups (P>0.05). A significant difference in cholesterol levels were observed between patients with different genotypes (P